Bionomics Stock (NASDAQ:BNOX), Trade Ideas

Bionomics Ltd is a global, clinical-stage biopharmaceutical company. It is primarily engaged in the development of therapeutics for diseases of the central nervous system and cancer. The company's reportable segment is the Drug Discovery and Development segment which is engaged in the discovery, development, and commercialization of compounds to match a target product profile. The company generates all of its revenues from Australia.

BNOX

Biotech

News

General

Bionomics&#39; Phase 2b ATTUNE trial on BNC210 for PTSD. Discover statistically significant improvements in symptom severity, cognition, mood, depressive symptoms, and sleep without sedation or cognitive impairment.

Bionomics Reveals Detailed Data From PTSD Trial, Stock Soars

Cannabis

Penny Stocks

Psychedelics

Regulations

Markets

Bionomics Meets The FDA: Lead Drug Candidate For Social Anxiety Heads To Phase 3

ATAI

CMPS

CYBN

DRUG

ENVB

GHRS

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

IXHL

LSDI

MNMD

PSIL

SILO

Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares



Psyched: Steve Cohen&#39;s New Biopharma Bet, California Gov. Authorizes Medical Psychedelics &amp; More

Bionomics Limited - American Depository Shares

Bionomics Ltd

WIIM

ENPH

Enphase Energy shares are trading higher after Barclays upgraded the stock from Equal-Weight to Overweight.

Keybanc analyst Brett Fishbin maintains ResMed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) with a Overweight and raises the price target from $227 to $238.

Price Target

Analyst Ratings

Keybanc Maintains Overweight on ResMed, Raises Price Target to $238

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a <a href="https://www.benzinga.com/yield-investments">high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the industrials sector.
<h3 class="wp-block-heading">Kennametal Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMT#NYSE">KMT</a>)</h3>
<ul>
<li>Dividend Yield: 3.37%</li>
<li>Barclays analyst Julian Mitchell maintained an Equal-Weight rating and cut the price target from $25 to $24 on April 2. This analyst has an accuracy rate of 77%.</li>
<li>JP Morgan analyst Tami Zakaria maintained an Underweight rating and lowered the price target from $26 to $24 on Feb. 8. This analyst has an accuracy rate of 76%.</li>
<li>Recent News: Kennametal said it will host its third quarter fiscal year 2024 earnings call on Wednesday, May 8.</li>
</ul>
<h3 class="wp-block-heading">C.H. Robinson Worldwide, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>)</h3>
<ul>
<li>Dividend Yield: 3.47%</li>
<li>B of A Securities analyst Ken Hoexter maintained an Underperform rating and cut the price target from $70 to $68 on April 15, 2024. This analyst has an accuracy rate of 70%.</li>
<li>JP Morgan analyst Brian Ossenbeck maintained an Underweight rating and slashed the price target from $75 to $70 on April 9. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: C.H. Robinson Worldwide said it will issue its first quarter results after the closing bell on Wednesday, May 1.</li>
</ul>
<h3 class="wp-block-heading">MSC Industrial Direct Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>)</h3>
<ul>
<li>Dividend Yield: 3.56%</li>
<li>Stephens &amp; Co. analyst Tommy Moll reiterated an Overweight rating with a price target of $110 on April 1. This analyst has an accuracy rate of 75%.</li>
<li>Keybanc analyst Ken Newman maintained an Overweight rating and cut the price target from $105 to $102 on Jan. 10. This analyst has an accuracy rate of 80%.</li>
<li>Recent News: On March 28, MSC Industrial Direct posted better-than-expected quarterly earnings.</li>
</ul>
Read More: <a href="https://www.benzinga.com/news/earnings/24/04/38452338/microsoft-alphabet-and-3-stocks-to-watch-heading-into-friday">Microsoft, Alphabet And 3 Stocks To Watch Heading Into Friday</a>

Dividends

Pre-Market Outlook

Trading Ideas

CHRW

Wall Street's Most Accurate Analysts' Views On 3 Industrials Stocks With Over 3% Dividend Yields

Comfort Systems shares are trading higher after the company reported better-than-expected Q1 financial results and increased its quarterly dividend.

Evercore ISI Group analyst Mark Lipacis maintains Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) with a In-Line and lowers the price target from $40 to $36.

INTC

Evercore ISI Group Maintains In-Line on Intel, Lowers Price Target to $36

The Novera QPU Partner Program aims to enable high-performing, on-premises quantum computing by creating an ecosystem of quantum computing hardware, software, and service providers who build and offer integral components of a functional quantum computing system. Novera QPU customers can work with Novera QPU partners to build a quantum computer powered by the Novera QPU that satisfies their system requirements and quantum computing research objectives.
BERKELEY, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) ("Rigetti" or the "Company"), a pioneer in full-stack quantum-classical computing, announces the launch of the Novera&#x2122; QPU Partner Program. The Novera QPU Partner Program is an ecosystem of quantum computing hardware, software and service providers who build and offer integral components of a functional quantum computing system. Novera QPU customers who need control systems, a dilution refrigerator, quantum computing software tools, or integration services can integrate their Novera QPU with Novera QPU Partners' technology with the assurance of compatibility and quality. &nbsp;
The founding members of the Novera QPU Partner Program include some of Rigetti's most long-time partners and are leaders in their respective areas of quantum computing technology:
<ul>
<li>Cryogenics: Bluefors</li>
<li>Control Systems:
<ul>
<li>Quantum Machines</li>
<li>Zurich Instruments</li>
</ul>
</li>
<li>Software:
<ul>
<li>Q-CTRL</li>
<li>Strangeworks</li>
<li>Classiq</li>
<li>Horizon Quantum Computing</li>
</ul>
</li>
<li>Integration and Service Providers:
<ul>
<li>TreQ</li>
<li>ParTec AG</li>
</ul>
</li>
<li>QEC Solutions: Riverlane</li>
</ul>
Rigetti intends on growing the Novera QPU Partner Program with additional partners on an ongoing basis.
The Novera QPU is a 9-qubit quantum processing unit (QPU) based on the Company's fourth generation Ankaa&#x2122;-class architecture featuring tunable couplers and a square lattice for denser connectivity and fast 2-qubit operations. The Novera QPU is manufactured in Rigetti's Fab-1, the industry's first dedicated and integrated quantum device manufacturing facility.
The Novera QPU includes all of the hardware below the mixing chamber plate (MXC) of a dilution refrigerator. In addition to a 9-qubit chip with a 3x3 array of tunable transmons, a 5-qubit chip with no tunable couplers or qubit-qubit coupling which can be used for developing and characterizing single-qubit operations on a simpler circuit, the Novera QPU components include:
<ul>
<li>A puck that contains both the 9-qubit and 5-qubit chips, interposers and a PCB to route signals to SMPM connectors at the puck periphery.</li>
<li>A tower that hangs from the MXC and connects coaxial cables between the puck and the SMA patch panel. The tower delivers cooling power from the MXC to the chips.</li>
<li>Shields that surround the tower to isolate the puck from infrared radiation and stray magnetic fields.</li>
<li>Payload brackets and a signal chain installed around the tower with mounted signal conditioning devices, including ferrite isolators, diplexers, filters, and optional quantum-limited amplifiers.</li>
</ul>
While a QPU is the core of a quantum computer, in order to have a functioning quantum computing system, the installation must also include (1) a dilution refrigerator and (2) a control system. Depending on a customer's research goals, system requirements, and use cases, there are also a variety of quantum software and integration resources that can be integrated with the Novera QPU.
Dr. Subodh Kulkarni, Rigetti CEO, said: "With the Novera QPU, we have a unique opportunity to support the development of on-premises quantum computing capabilities worldwide. At Rigetti, we are experts at overcoming the challenges of building, installing, and supporting a quantum computing system. After a decade in the quantum computing industry, we've also forged long lasting partnerships with world-leading quantum technology companies whose collaborations and expertise helped us advance our capabilities even further. We want to empower Novera QPU customers with an ecosystem of our trusted partners to support their own quantum computing research pursuits, and to help prepare us for a quantum-ready society."
David Gunnarsson, Bluefors CTO, said: "Bluefors' Dilution Refrigerator Measurement Systems are renowned for their unmatched reliability, and today we have more than 1,250 units in operation worldwide. It's important for us to continue to innovate and develop critical components of a high performing quantum computer. Bluefors next generation gas handling system supports the deployment and easy to use cryogenics for on-premises quantum systems. We have the capability to support our customers with best in industry lead time and we are thrilled to be leading the field and pushing the boundaries of ultra-low temperature cooling."
Nir Minerbi, Classiq CEO, said: "Quantum computing relies on bringing together a collection of technologies in order to achieve the best fitting and performing solution. Classiq is proud to be providing efficient, scalable quantum computing software to facilitate best-practice algorithm development with Novera."
Joe Fitzsimons, Horizon Quantum Computing CEO, said: "Rigetti was one of the pioneers of cloud-based quantum computing, and we are delighted to partner with them as Rigetti processors begin to power on-premises systems. As the industry pushes towards quantum advantage, a strong ecosystem and close collaboration between hardware and software efforts is more important than ever. The Novera QPU Partner Program is a welcome new instrument for building collaboration and allowing for tight integration between technologies at all levels of the quantum computing stack."
Bernhard Frohwitter, ParTec AG CEO, said: "The Novera QPU Partner Program is an essential building block in ParTec's strategy of becoming a quantum computing system integrator, building full-stack solutions using a component-based design that relies on a supply chain of quantum technology providers. ParTec looks forward to integrating the Novera QPU in our holistic quantum computer solutions and working with customers on unleashing its potential."
Michael J. Biercuk, Q-CTRL CEO and Founder, said: "The team at Q-CTRL has been excited to work with the Rigetti team to show how the right combination of hardware and infrastructure software can help deliver huge capabilities&nbsp;and performance enhancements to end users. Now we're thrilled to be delivering this capability directly to researchers and customers of the Novera QPU to help them achieve their goals using quantum computing with optimal performance."
Dr. Itamar Sivan, co-founder and CEO of Quantum Machines, said: "We're excited to be one of the founding members of the Novera QPU Partner Program. OPX1000 enables users to control their Novera QPU in real-time and push the boundaries of what algorithms and experiments can be performed. By integrating our OPX family of high-performance, processor-based controllers with Rigetti's advanced QPU technology, we are paving the path to accessible, powerful quantum computing solutions and accelerated time-to-market. Our partnership embodies our commitment to delivering industry-leading quantum control capabilities that push the boundaries of our industry closer to real-world applications."
Steve Brierley, founder and CEO of Riverlane said: "Together, Riverlane's Quantum Error Correction Stack and Rigetti's Novera QPU go hand in glove. End users can use our stack holistically or in parts. This includes our hardware decoder, optimized for Rigetti's architecture; our suite of public and proprietary software decoders, ‘QEC Explorer'; and ‘Aqueduct', our open quantum experiment management platform."
whurley, founder and CEO of Strangeworks, said: ​​"This Partner Program will enable organizations to procure and build powerful quantum computers at a fraction of the price of commercial systems today. We are thrilled to be one of the first members of the Novera QPU Partner Program and deepen our existing partnership with Rigetti."
Mandy Birch, CEO of TreQ said: "TreQ is delighted to partner with Rigetti to build and operate on-premises quantum computing systems that include the Novera QPU. We look forward to supporting pathfinders around the world who are expediting useful and usable next-gen computing infrastructure to elevate their businesses, institutions, and communities."
Moritz Kirste, Head of Business Development Quantum Technologies at Zurich Instruments, said: "We are excited to be one of the founding members of Rigetti's Novera QPU Partner Program. Zurich Instruments started contributing to quantum technologies in 2015, and ever since we are committed to Swiss quality standards in R&amp;D and in production. This partnership opens new pathways to support our customers with full-stack solutions, locally by our experts in seven international offices."
Among the early adopters of small-scale, high performing QPUs like the Novera QPU, are government agencies. The first two Novera QPU sales were to leading US government labs — the Superconducting Quantum Materials and Systems Center (SQMS) led by Fermilab, and the Air Force Research Lab (AFRL). Rigetti also recently sold a Novera QPU to Horizon Quantum Computing for their first quantum computing system, to be installed in their new hardware testbed in Singapore. Quantum computing researchers across academia and industry are also beginning to invest in this technology as it is a promising resource to advance quantum computing workforce development.
The Novera QPU Partner Program launch follows Rigetti's recent achievements with its larger-scale Ankaa-class quantum systems. Rigetti's 84-qubit Ankaa-2 system, which is available over the cloud via Rigetti's Quantum Cloud Services (QCS&#xAE;) cloud computing platform, recently achieved a 98% median 2-qubit gate fidelity. This performance marks a 2.5X increase in error performance compared to the Company's previous QPUs. Rigetti was also recently awarded an Innovate UK competition to deliver a 24-qubit Ankaa-class quantum computing system to the UK's National Quantum Computing Centre.

RGTI

Rigetti Computing Launches The Novera QPU Partner Program

The most oversold stocks in the materials sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>)</h3>
<ul>
<li>United States Steel is expected to release financial results for the first quarter 2024 on Thursday, May 2. The company's stock fell around 9% over the past month and has a <a href="https://www.benzinga.com/quote/X">52-week low of $20.40</a>.</li>
<li>RSI Value: 29.95</li>
<li>X Price Action: Shares of United States Steel gained 1.6% to close at $37.17 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Compass Minerals International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On March 25, Compass Minerals announced the U.S. Forest Service has informed the company that it will not be entering into a contract for the use of magnesium chloride-based aerial fire retardants for the 2024 fire season. The company's stock fell around 8% over the past month. It <a href="https://www.benzinga.com/quote/CMP">has a 52-week low</a> of $11.85.</li>
<li>RSI Value: 28.86</li>
<li>CMP Price Action: Shares of Compass Minerals fell 1.3% to close at $12.62 on Thursday.</li>
</ul>
<h2 class="wp-block-heading">Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>)</h2>
<ul>
<li>On April 22, Nucor reported worse-than-expected first-quarter financial results. "Nucor's performance continues to be strong even as steel market conditions have come off their post-pandemic record highs," said Leon Topalian, Nucor's CEO. "We also took several bold steps to advance our growth, sustainability and commercial strategies during the first quarter." The company's stock fell around 8% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/NUE">low of $129.79</a></li>
<li>RSI Value: 29.36</li>
<li>NUE Price Action: Shares of Nucor rose 1.8% to close at $175.88 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>)</h3>
<ul>
<li>On April 22, Cleveland-Cliffs reported first-quarter revenue of $5.2 billion, which missed the consensus estimate of $5.346 billion. "Our first quarter results were highlighted by the resiliency of automotive production in the United States, which helped to offset a temporary buyers strike from service centers in January and February," said Lourenco Goncalves, chairman, president and CEO of Cleveland-Cliffs. The company's shares lost around 12% over the past five days. The company's 52-week low is $13.61.</li>
<li>RSI Value: 25.26</li>
<li>CLF Price Action: Shares of Cleveland-Cliffs fell 0.5% to close at $18.23 on Thursday.</li>
</ul>
Now Check This Out: <a href="https://www.benzinga.com/news/earnings/24/04/38452338/microsoft-alphabet-and-3-stocks-to-watch-heading-into-friday">Microsoft, Alphabet And 3 Stocks To Watch Heading Into Friday</a>

Long Ideas

Top 4 Materials Stocks That May Explode In Q2

I am writing to share some exciting news regarding WiSA Technologies and our upcoming Special Meeting of Stockholders on May 13, 2024.
At its core, WiSA Technologies is an innovative company, a company whose dynamic products are built on a strong R&amp;D foundation. Over the past decade, we have been at the forefront of innovation in the audio/video entertainment space. Our bold vision to deliver a superior at-home entertainment listening experience has guided us to prioritize significant investments in R&amp;D in order to create a company that is built to last. With this foundation firmly in place, we strongly believe that, at this juncture, we have set the stage for sustainable long-term success because we have a dynamic core product that will help us and our customers advance multichannel wireless audio to become the ubiquitous standard in the industry.
Our journey has been marked by several milestones:
Formation of a Strong Foundation: In our early years, we focused on building talented teams of R&amp;D, sales, marketing, and management, while fostering a culture that embraced our vision.
Industry Recognition: We formed the 70+ member WiSA Association focused on standardizing the delivery of multichannel wireless audio and we showcased our technology solutions at prestigious events like CES, forging strong relationships with the world's leading consumer electronics manufacturers.
Continuous Innovation: Year after year, we invested heavily in R&amp;D to introduce robust technology solutions to consumer electronics manufacturers.
Today, I am proud to say that WiSA Technologies is well-positioned to transform the spatial audio industry. Culminating from our years of hard work and investment in R&amp;D, we introduced a groundbreaking technology in 2023, WiSA E. This breakthrough represents a transformative milestone and new chapter for WiSA Technologies. Leading consumer electronics manufacturers are partnering with us to bring WiSA E to market through their channels and products by licensing our IP, which is expected to unlock new revenue streams for our company for years to come.
To realize the promise of WiSA E, we are introducing a new program, called Propel, that will consist of several strategic initiatives over the next 18 months that include:
Enhanced Value for Shareholders: Standardizing industry solutions and implementing initiatives to achieve consistent revenue performance, reduce infrastructure costs and maximize long-term shareholder value.
Revenue Growth: Creating new revenue streams that are expected to significantly impact our company's top-line growth. This includes enhancing our WiSA E technology to attract partnerships with TV/Audio speaker and chip manufacturers, resulting in increased licensing agreements and certifications.
Path to Profitability: Developing stringent specifications compliance and close working partnerships with consumer electronics manufacturers and chip makers to produce high-volume, lower cost solutions that will deliver positive benefits to our bottom line.
Industry Leadership: Expanding interbrand operability among premier audio manufacturers and delivering premium technology solutions to mass-market audio systems. WiSA Technologies aims to solidify its position as an industry innovator through this expansion.
Strong Governance: Implementing amendments to our certificate of incorporation and bylaws. These changes are expected to provide WiSA Technologies with the flexibility and governance needed to swiftly execute and adapt to market demands.
To achieve these ambitious goals, we need your support. At the upcoming Special Meeting of Stockholders, we will be presenting several proposals that are crucial for the successful execution of our Propel program:
Proposal #1: Authorize a Reverse Stock Split&nbsp; Proposal #2: Approve an Amendment to the Certificate of Incorporation to Allow the Board of Directors to Amend the Bylaws&nbsp; Proposal #3: Approve Issuance of Shares upon Exercise of February 2024 Warrants&nbsp; Proposal #4: Approve Issuance of Shares upon Exercise of March 2024 Warrants&nbsp; Proposal #5: Consider and Act Upon Other Business
The WiSA Board of Directors and I wholeheartedly recommend that you VOTE FOR each of the proposals.
Each of these proposals is vital for us to move forward with confidence and realize the full potential of WiSA E and Propel. I urge you to read about these proposals in detail in the Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission.
Your vote is important regardless of the number of shares you own. Please take the time to vote today to ensure your vote is received prior to the special meeting on May 13, 2024. For assistance with voting your shares, please reach out to our proxy solicitor, Lioness Consulting, via email at <a href="mailto:info@lionessconsultingllc.com">info@lionessconsultingllc.com</a>.
Thank you for your ongoing support of our vision and our efforts to be the industry standard for wireless innovation.
Warm regards,
Brett Moyer
CEO and Founder&nbsp; WiSA Technologies Inc.

WISA

WiSA Technologies Issues Letter To Shareholders

Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) reported better-than-expected first-quarter results and issued upbeat guidance for FY24, after the <a href="https://www.benzinga.com/quote/TYL/earnings">closing bell on Wednesday</a>.
Tyler Technologies posted quarterly earnings of $2.20 per share, beating market expectations of $2.04 per share. The company's quarterly sales came in at $512.36 million topping estimates of $507.15 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Tyler Technologies said it sees FY24 earnings of $9.10 to $9.30 per share, versus estimates of $9.02 per share. The company expects revenue of $2.11 billion to $2.14 billion, versus expectations of 2.12 billion.
Tyler Technologies shares gained 9.3% to close at $458.07 on Thursday.
These analysts made changes to their price targets on Tyler Technologies following earnings announcement.
<ul>
<li>Oppenheimer increased the price target on Tyler Technologies from $480 to $500.. Oppenheimer analyst Ken Wong maintained an Outperform rating.</li>
<li>Baird boosted the price target on Tyler Technologies from $500 to $525. Baird analyst Rob Oliver maintained an Outperform rating.</li>
<li>Needham analyst Joshua Reilly, meanwhile, reiterated Tyler Technologies with a Buy and maintained a $500 price target.</li>
</ul>
Read More: <a href="https://www.benzinga.com/news/earnings/24/04/38452338/microsoft-alphabet-and-3-stocks-to-watch-heading-into-friday">Microsoft, Alphabet And 3 Stocks To Watch Heading Into Friday</a>

Earnings

These Analysts Boost Their Forecasts On Tyler Technologies Following Strong Earnings

Offerings

Hilton Worldwide Files Shelf Registration For Stock, Debt

Burke &amp; Herbert Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHRB#NASDAQ">BHRB</a>) reported quarterly earnings of $0.69 per share. This is a 31 percent decrease over earnings of $1.00 per share from the same period last year. The company reported $26.39 million in sales this quarter. This is a 8.98 percent decrease over sales of $28.99 million the same period last year.

BHRB

Burke & Herbert Financial Q1 EPS $0.69 Down From $1.00 YoY, Sales $26.39M Down From $28.99M YoY

— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade&nbsp;—— Positive opinion based on results from
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade&nbsp;—
— Positive opinion based on results from FRESCO-2 Phase III clinical trial&nbsp;—

HUTCHMED Announces Positive CHMP Opinion For Fruquintinib In Previously Treated Metastatic Colorectal Cancer Received By Takeda

Tenaris shares are trading lower after the company reported Q1 financial results.

BDRX

Biodexa shares are trading higher after the company entered an exclusive license agreement with Rapamycin Holdings for the rights to eRapa.

The Federal Reserve&#8217;s preferred measure of inflation – the Personal Consumption Expenditure (PCE) price index – rose more than expected in March, confirming concerning signs of a resurgence in inflationary pressures in the first <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38434513/us-growth-slows-in-q1-yet-inflation-acceleration-signals-stagflation-the-worst-poss">quarter of the year</a>.
The higher-than-expected PCE report serves as a stark reality check for traders, further postponing expectations of a Federal Reserve rate cut that had already been dwindling in recent weeks.
<h3 class="wp-block-heading">March PCE Report: Key Highlights</h3>
<ul>
<li>The headline PCE price index rose from 2.5% in February 2024 to 2.7% year-on-year in March, beating forecasts of a 2.6% increase, the Bureau of Economic Analysis reported Friday. </li>
<li>On a monthly basis, the headline PCE accelerated by 0.3%, unchanged from the 0.3% recorded in February, and matching expectations. </li>
<li>When excluding energy and food expenses, the core PCE price index held steady at 2.8% year-on-year, surpassing predictions of a decline to 2.6%. </li>
<li>On a month-over-month basis, the core PCE advanced at a 0.3% pace, unchanged from both the previous and expected 0.3%. </li>
</ul>
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Indicator</th>
<th>February 2024</th>
<th>March 2024</th>
<th>March (expected)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headline PCE YoY</td>
<td>2.5%</td>
<td>2.7%</td>
<td>2.6%</td>
</tr>
<tr>
<td>Headline PCE MoM</td>
<td>0.3%</td>
<td>0.3%</td>
<td>0.3%</td>
</tr>
<tr>
<td>Core PCE YoY (excl. energy &amp; food)</td>
<td>2.8%</td>
<td>2.8%</td>
<td>2.6%</td>
</tr>
<tr>
<td>Core PCE MoM (excl. energy &amp; food)</td>
<td>0.3%</td>
<td>0.3%</td>
<td>0.3%</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Market Reactions</h3>
Market-implied probabilities indicated a 60% chance of a rate cut by September 2024, and priced in cumulatively 35 basis points of rate cuts by year-end, implying just one rate cut. 
The U.S. dollar index (DXY), as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), inched higher minutes after the PCE release. 
Futures on major U.S. averages rallied during Friday&#8217;s pre-market trading following upbeat quarterly results from Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>), which offset Thursday&#8217;s negative sentiment stemming from Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)&#8217;s weaker-than-expected guidance.
However, with the Fed&#8217;s preferred inflation gauge pushing any rate cut talks further into the future, traders may potentially brace for macro-related volatility in the last session of the week.
Read now: <a href="https://www.benzinga.com/news/earnings/24/04/38455462/wall-street-futures-ride-high-on-microsoft-alphabet-cheer-but-will-inflation-data-burst-the-bubble-">Wall Street Futures Ride High On Microsoft, Alphabet Cheer, But Will Inflation Data Burst The Bubble? Why This Analyst Thinks Bull Run Isn&#8217;t Over Yet</a>
Photo: Shutterstock

Macro Notification

Currency ETFs

Econ #s

Economics

ETFs

GOOGL

MSFT

PowerShares DB US Dollar Index Bullish Fund

Fed's Key Inflation Indicator Hits 2.8%, Dashes Rate Cut Hopes; Traders On Alert

Evercore ISI Group analyst Mark Mahaney maintains Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) with a Outperform and raises the price target from $160 to $220.

GOOG

Evercore ISI Group Maintains Outperform on Alphabet, Raises Price Target to $220

Keybanc analyst Jason Celino maintains AppFolio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPF#NASDAQ">APPF</a>) with a Overweight and raises the price target from $264 to $275.

APPF

Keybanc Maintains Overweight on AppFolio, Raises Price Target to $275

<ul>
<li>$15&nbsp;million CIRM Grant Supports the Ongoing Phase 1 TRAVERSE Trial Evaluating ALLO-316 in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
<ul>
<li>ALLO-316 Illustrates Proof-of-Concept in RCC and the Potential of Dagger&#xAE; Technology to Optimize CAR T Cell Expansion and Persistence</li>
</ul>
</li>
</ul>

Contracts

ALLO

Allogene Therapeutics Awarded $15M Grant From California Institute For Regenerative Medicine To Advance Development Of Allogeneic CAR T In Renal Cell Carcinoma

Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company")
Biodexa Enters Into Exclusive License to eRapa&#x2122;, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
Worldwide rights come with $17 million in non-dilutive grant funding for Pivotal Phase 3 trial in FAP
An estimated 100,000 in U.S. and Europe are afflicted with FAP, precancerous polyps that typically lead to surgical removal of the colon and/or rectum
In FAP, eRapa holds the potential of delaying or preventing surgical intervention
Multiple opportunities seen in other indications, including bladder and prostate cancers
<ul>
<li>FAP is a substantially genetic orphan disease for which there are no approved therapeutic options; the current standard of care is surveillance and surgery</li>
<li>Phase 3 FAP program is supported by a $17 million grant awarded from the Cancer Prevention and Research Institute of Texas ("CPRIT") in a competitive process</li>
<li>Phase 2 results in FAP to be presented at two leading scientific conferences in Q2 ‘24</li>
<li>Ongoing Phase 2 study in Non-muscle Invasive Bladder Cancer expected to read-out in Q2 ‘25</li>
<li>Phase 2 study in NMI Bladder Cancer supported by $3 million grant from National Cancer Institute, part of the National Institutes of Health &nbsp;</li>
</ul>
Biodexa Pharmaceuticals PLC, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced it entered into a definitive agreement with Rapamycin Holdings Inc. (d/b/a Emtora Biosciences) ("Emtora") for the rights to eRapa under an exclusive, worldwide license (with the ability to grant sublicenses) to develop, manufacture, commercialize and otherwise advance the clinical potential of eRapa. &nbsp;&nbsp; &nbsp;&nbsp;
Stephen Stamp, CEO and CFO of Biodexa said, "Acquiring a Phase 3 ready asset, particularly one supported by $17 million of non-dilutive grant funding, significantly advances Biodexa's oncology pipeline and adds numerous valuation catalysts for our stakeholders. We are delighted to be working with the Emtora team which has excelled in bringing eRapa close to the end of Phase 2 in Non-muscle Invasive Bladder Cancer and to the beginning of a Phase 3 trial in FAP, a devastating disease for which there is currently no approved pharmacological agent for altering its progression. Left untreated, it almost always leads to incredibly invasive surgery and a major deterioration in the quality of life."
Stephen Dufilho, Executive Chairman of Emtora added, "The transaction with Biodexa is the culmination of a decade-long effort to advance our potentially game-changing eRapa to a registrational Phase 3 trial - and ultimately to patients in need. Our story began in San Antonio – where eRapa was originally invented at the University of Texas and funded in part by grants from the Cancer Prevention Research Institute of Texas. We thank the scientists, clinicians, investors and biotech executives that supported our efforts to reach this important milestone. We look forward to working with the Biodexa team as we embark upon this next chapter."
About eRapa eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorgenesis1. Rapamycin is approved in the US for organ rejection in renal transplantation as Rapamune&#xAE;(Pfizer). Through the use of nanotechnology and pH sensitive polymers, eRapa is designed to address the poor bioavailability, variable pharmacokinetics and toxicity generally associated with the currently available forms of rapamycin. eRapa is protected by a number of issued patents which extend through 2035, with other pending applications potentially providing further protection beyond 2035.

Biodexa Enters Into Exclusive License To eRapa, A Phase 3 Ready Asset For The Treatment Of Familial Adenomatous Polyposis; Worldwide Rights Come With $17M In Non-Dilutive Grant Funding For Pivotal Phase 3 Trial In FAP

Meta Platforms Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) Threads and Instagram head Adam Mosseri announced Thursday that Threads is rolling out a new &#8220;Hidden Words&#8221; feature.&nbsp;
The feature allows users to filter offensive or unwanted words, phrases, and emojis from their feeds and mentions.&nbsp;
The feature comes with preset filters and allows users to add custom words and phrases via the settings, which they can deactivate at any time, TechCrunch&nbsp;<a target="_blank" href="https://techcrunch.com/2024/04/25/threads-launches-a-mute-feature-for-words-teases-controls-for-quote-posts/" rel="noreferrer noopener">reports</a>.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/04/38201197/metas-instagram-takes-steps-against-sextortion-of-teenage-users" rel="noreferrer noopener">Meta&#8217;s Instagram Takes Steps Against Sextortion of Teenage Users</a>
Similarly,&nbsp;Match Group, Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) dating app Hinge launched its &#8220;Hidden Words&#8221; feature earlier this week, which blocks comments containing specific unwanted words.
The feature on Threads filters content across the &#8220;Following&#8221; and &#8220;For You&#8221; feeds, search results, profiles, and replies to posts.&nbsp;
Moreover, Threads already provides options for users to control who can reply to their posts—whether it&#8217;s anyone, profiles they follow, or just those mentioned—and who they can&nbsp;mention&nbsp;in posts, replies, and bios, with settings including everyone, profiles they follow, or no one.
Threads is also planning to introduce controls for quoting posts. Soon, users will be able to restrict who can quote their posts and offer the ability to manually unquote posts.&nbsp;
Additionally, Threads is testing a feature allowing users to mute notifications from post interactions. Threads is actively introducing new functionalities, such as testing automatic post archiving.
During a recent Meta earnings call, Mark Zuckerberg highlighted that Threads has reached over 150 million monthly active users.
The&nbsp;U.S.&nbsp;Federal Trade Commission (FTC)&nbsp;<a target="_blank" href="https://www.benzinga.com/government/24/03/37670716/metas-battle-with-ftc-thickens-court-rejects-bid-to-stop-privacy-investigation" rel="noreferrer noopener">continues to probe</a>&nbsp;the privacy practices of Meta&#8217;s Facebook unit.&nbsp;
Despite Meta arguing that it has paid a $5 billion fine and implemented numerous safeguards under a 2020 privacy settlement, the FTC aims to strengthen the agreement, especially concerning&nbsp;the use of&nbsp;minors&#8217; data and&nbsp;the application of&nbsp;facial recognition technology.&nbsp;
The agency has criticized Meta for failing to protect children&#8217;s privacy&nbsp;adequately.
Recently, Meta announced&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/04/38265971/metas-threads-introduces-real-time-recent-filter-to-enhance-search-experience" rel="noreferrer noopener">that it would</a>&nbsp;shut down its Threads service in Turkey on April 29 following a provisional directive from the Turkish Competition Authority (TCA). Additionally, Meta had to postpone the introduction of Threads to the European Union due to the Digital Markets Act (DMA).
Meta stock gained 111% in the last 12 months. Investors can gain exposure to the stock via&nbsp;The Communication Services Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) and&nbsp;Fidelity MSCI Communication Services Index ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCOM#NYSE">FCOM</a>).
Price Action:&nbsp;META shares are&nbsp;trading higher by 1.09% at $446.21 premarket&nbsp;at the last check Friday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo via Shutterstock.

Tech

Media

FCOM

MTCH

Meta's Threads Enhances User Control with New Features

AEHR, TUP and VTGN are among pre market gainers

Penumbra, Verve Therapeutics among healthcare movers

Bionomics presents data on reliability of the Subjective Units of Distress Scale

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Bionomics (BNOX – Research Report), with a price targe...

Bionomics: A Strong Buy on Robust Clinical and Regulatory Milestones

XPEV, BILI and ROMA among pre-market losers

Bionomics (BNOX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C....

Bionomics: A Strong Buy on Clinical and Regulatory Milestones

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Small-cap stocks are particularly vulnerable to higher interest rates. So it&rsquo;s not surprising that many of these stocks are struggling in a higher-for-longer rate environment. But the when, not if, proposition for lower interest rates makes this a time to look for strong buy stocks under $20. &nbsp;



According to Fed chair Jerome Powell, the much-anticipated interest rate cuts won&rsquo;t be happening any time soon. However, Powell did concede that the Federal Reserve is likely to cut rates at least three times in 2024. &nbsp;



Does that mean it&rsquo;s time to dive in with both feet? Probably not. But it&rsquo;s a great time to be getting your watchlist together. And that&rsquo;s the purpose of looking at strong buy stocks under $20. Many of these small-cap stocks aren&rsquo;t heavily covered by analysts. However, when these companies get even one Strong Buy rating, it&rsquo;s worth investigating.&nbsp;



The stocks on this list, may not have Strong Buy ratings, but they do have a consensus Buy rating and catalysts that suggest they are ready to make a move higher. &nbsp;



<h2>Uranium Energy (UEC)&nbsp;</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/05/uranium-1600-300x169.png" alt="Powdered and solid uranium in front of a white background."><div>Source: RHJPhtotos / Shutterstock</div></div>


The bullish case for Uranium Energy (NYSEAMERICAN:<a href="https://investorplace.com/stock-quotes/uec-stock-quote/">UEC</a>) is straightforward. The spot price of uranium recently hit 15-year highs. <a href="https://investorplace.com/2024/01/3-top-rated-russell-2000-stocks-for-your-2024-watchlist/" target="_blank">Demand is expected to outpace supply</a> for the foreseeable future as climate change advocates embrace nuclear energy as a clean form of energy. &nbsp;



Is that enough reason to buy a stock that&rsquo;s up 110.9% in the last 12 months? The answer lies in whether you believe that Uranium Energy can hit its production targets. To that end, the company recently <a href="https://www.uraniumenergy.com/news/releases/index.php?content_id=1046" target="_blank">announced an imminent restart</a> of uranium production at its Christensen Ranch In-Situ Recovery (<a href="https://investorplace.com/stock-quotes/isr-stock-quote/">ISR</a>) operations in Wyoming.&nbsp;



Uranium Energy also plans to restart production at its South Texas Hub &amp; Spoke ISR Platform. Put together, the company controls the largest S-K 1300 compliant ISR resource base in the U.S. with over 75 million lbs. of Measured and Indicated resources. &nbsp;&nbsp;



The risk is the company&rsquo;s own forecast for lower earnings in the next 12 months. Nevertheless, at this point, analysts are shrugging that off. UEC stock has a <a href="https://www.tradingview.com/chart/?symbol=AMEX%3AUEC&amp;utm_source=www.marketbeat.com&amp;utm_medium=widget&amp;utm_campaign=chart-logo&amp;utm_term=AMEX%3AUEC" target="_blank">$10.30 consensus price target</a> with all five analysts that issued a rating giving the stock a Strong Buy. &nbsp;



<h2>Hudbay Minerals (HBM)&nbsp;</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/copper-1600-300x169.png" alt="Copper ingots in a stack on a white background. Copper stocks."><div>Source: ppart / Shutterstock</div></div>


Hudbay Minerals (NYSE:<a href="https://investorplace.com/stock-quotes/hbm-stock-quote/">HBM</a>) gives investors a different way to invest in metals and mining. The company is one of the world&rsquo;s leading copper miners which accounts for approximately 50% of Hudbay&rsquo;s revenue. 



Investors are discovering that the global transition to renewable energy is likely to take longer than expected. That&rsquo;s reflected in HBM stock, which has been flat in the last 12 months. &nbsp;



But <a href="https://investorplace.com/2024/01/precious-metals-stocks-2024-3-names-offering-strong-growth/" target="_blank">copper will be needed</a> for many applications including electric vehicles and to help update our existing electric infrastructure. To quantify that, consider that to reach the target of net zero carbon emissions by 2050, the world will need to <a href="https://investorplace.com/2023/04/7-growth-stocks-that-are-trading-at-a-bargain-price/" target="_blank">mine 1.4 billion tons of copper</a>. And to put that into perspective, the world has only mined 700 million tons of copper in all of history. &nbsp;



That means that a miner like Hudbay Minerals has a long runway. The company is forecasting 318% earnings growth that is starting to get priced into analysts&rsquo; estimates.&nbsp;



In the next 12 to 18 months, analysts give HBM stock a consensus price target that is 30% higher than its price as of February 1, 2024. And 12 out of 14 analysts have a <a href="https://www.tradingview.com/chart/?symbol=NYSE%3AHBM&amp;utm_source=www.marketbeat.com&amp;utm_medium=widget&amp;utm_campaign=chart-logo&amp;utm_term=NYSE%3AHBM" target="_blank">Strong Buy or Buy rating</a> on the stock. &nbsp;



<h2>Bionomics (BNOX)&nbsp;</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div>


I put Bionomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bnox-stock-quote/">BNOX</a>) on this list of strong buy stocks under $20 when I saw a forecast of 1,257% share price appreciation in the next 12 to 18 months. Admittedly that&rsquo;s only two analysts, but then again, the clinical-stage biotechnology company trades for less than dollar a share as of this writing. <a href="https://investorplace.com/stock-types/penny-stocks/">Penny stocks</a> don&rsquo;t generally receive strong analyst coverage. &nbsp; 



But as investors know, when it comes to <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a>, things can change fast. In the case of Bionomics, the catalyst is coming from the <a href="https://www.bionomics.com.au/pipeline/" target="_blank">company&rsquo;s lead candidate, BNC210</a>. The therapeutic is being studied for different indicators. And as of February 1, the company is planning to <a href="https://ir.bionomics.com.au/news-releases/news-release-details/bionomics-provides-review-2023-and-2024-plans" target="_blank">initiate a first Phase 3 study</a> of BNC210 for social anxiety disorder (SAD). &nbsp;



Even with positive results, Bionomics won&rsquo;t be profitable in 2024. And since debuting in the public markets in 2022, investors have seen the stock drop by over 90%. This isn&rsquo;t without risk, but if you have a high risk tolerance and the willingness to wait on an uncertain outcome, BNOX stock may be a profitable fit. &nbsp;



<h2>Blade Air Mobility (BLDE)&nbsp;</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/blde-stock-1-300x169.jpg" alt="The Blade Air Mobility (BLDE) logo displayed on a smartphone screen."><div>Source: Wirestock Creators / Shutterstock.com</div></div>


Blade Air Mobility (NASDAQ:<a href="https://investorplace.com/stock-quotes/blde-stock-quote/">BLDE</a>) is another penny stock for this list. The concept of flying cars is becoming a reality. Blade Air isn&rsquo;t a pure play in the sector. But for now, they&rsquo;re serving as a crucial bridge, and will still have relevance even when electric vertical takeoff and landing (eVTOL) aircraft are available. 



But while eVTOL&rsquo;s may be the future of urban air mobility, Blade Air is most definitely the present. The company is seeing <a href="https://investorplace.com/2024/01/7-evtol-stocks-to-invest-in-the-full-range-of-air-mobility/" target="_blank">strong revenue growth</a> and with its asset-light business model (it doesn&rsquo;t own its aircraft) is closing in on profitability. That business model also means Blade&nbsp;should be able to make a <a href="https://d1io3yog0oux5.cloudfront.net/_c3af0482d6f839f2f20be72d549fb727/blade/db/1311/12005/pdf/2023.11+BLADE+-+Investor+Deck+vF.pdf" target="_blank">seamless transition to incorporate eVTOLs</a> when the time is right. &nbsp;



BLDE stock is up 43.75% in the last three months but is still down 33% in the last 12 months. Nevertheless, analysts are bullish on the stock giving it a $7.50 consensus price target which is 150% higher than its current price. And, all five analysts that have issued a rating give the stock a Strong Buy rating. &nbsp;&nbsp;



<h2>Groupon (GRPN)&nbsp;</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/grpn-stock-3-300x169.jpg" alt="a building sports a sign bearing the Groupon (GRPN) logo"><div>Source: Ken Wolter / Shutterstock.com</div></div>


It&rsquo;s been said that American&rsquo;s love a deal. But you would have hard time convincing Groupon (NASDAQ:<a href="https://investorplace.com/stock-quotes/grpn-stock-quote/">GRPN</a>) shareholders about the truth of that statement. The company&rsquo;s revenue is down sharply year-over-year and the company&rsquo;s earnings turned negative. &nbsp;



That&rsquo;s because companies have now figured out how to get their message &ndash; and their discounts &ndash; directly to consumers. &nbsp;



But Groupon is one of the strong buy stocks under $20 because of <a href="https://investorplace.com/2023/11/7-short-squeeze-stocks-that-could-serve-up-serious-rewards/" target="_blank">high short interest</a>. Yes, a short squeeze may not be the most convincing reason to buy a stock, but it&rsquo;s hard to ignore. &nbsp;



A look at the GRPN stock chart shows an interesting tug-of-war going on around the $14 level. The shorts are trying to push it down, but the 10-, 20- and 50-day simple moving averages show that the bulls are making a stand. &nbsp;



Again, this may not be the right reason to own the stock. But three out of four analysts give the stock a <a href="https://www.tradingview.com/chart/?symbol=NASDAQ%3AGRPN&amp;utm_source=www.marketbeat.com&amp;utm_medium=widget&amp;utm_campaign=chart-logo&amp;utm_term=NASDAQ%3AGRPN" target="_blank">Strong Buy or Buy rating</a> with a consensus price target that could take the stock over 18% higher.&nbsp;



<h2>Cemex (CX)&nbsp;</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/10/cement-cx-1600-300x169.jpg" alt="A person wearing work clothes scoops cement out of a bucket."><div>Source: chomplearn / Shutterstock.com</div></div>


Infrastructure spending will continue to flow through the economy in 2024. That should be bullish for Cemex (NYSE:<a href="https://investorplace.com/stock-quotes/cx-stock-quote/">CX</a>). Bridges, roads, buildings are just a few of the examples of applications that require concrete. This will keep demand for the products that Cemex supplies relatively steady. &nbsp;



I put the Mexican-based company on this list due to its leadership in sustainable concrete production. Cement product accounts for approximately 7% of global CO2 emissions and the company&rsquo;s <a href="https://www.cemex.com/products-solutions/vertua" target="_blank">Vertua product line</a> has features that have a low or neutral CO2 footprint.&nbsp;



But Cemex has more than just a story to make it one of the strong buy stocks under $20. The company is growing revenue year-over-year and projects a 38% gain in earnings in the next 12 months. Of all the stocks on this list CX stock has the most analyst coverage. 19 analysts have issued a rating and 16 give it either a Strong Buy or Buy rating. &nbsp;



<h2>BlackSky Technology (BKSY)&nbsp;</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/high-tech-spaceship-view-planets-300x169.png" alt="An image of the view from a high-tech spaceship looking out at planets and asteroids. space stocks"><div>Source: sdecoret / Shutterstock</div></div>


Investing in <a href="https://investorplace.com/industries/industrial/space/">space stocks</a> is not for the risk-averse investor. But if you&rsquo;re looking for an oversold name with some upside, BlackSky Technology (NYSE:<a href="https://investorplace.com/stock-quotes/bksy-stock-quote/">BKSY</a>) merits consideration. &nbsp;



BlackSky is a leader in delivering space-based intelligence to its customers. Not surprisingly, the company generates a significant portion of its revenue from U.S. government agencies. The company is growing revenue at an impressive pace. In its most recent earnings report, BlackSky reported record revenue that was 26% higher YOY and an 11% YOY growth in its high-margin imagery and analytics revenue. &nbsp;



BKSY is another penny stock on this list. It&rsquo;s not profitable at the moment, but projects it will be <a href="https://d1io3yog0oux5.cloudfront.net/_f6b4a2c9cd50eae317d58105eec42fc8/blacksky/db/856/7617/pdf/BKSY+Q3+2023+Earnings+Webcast+-+Final.pdf" target="_blank">adjusted EBITDA positive in the coming quarter</a>. Analysts are forecasting 116% growth in the next 12 months. And four out of five analysts give the stock a Strong Buy rating. &nbsp;



On the date of publication, Chris Markoch did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.&nbsp;
<div>Chris Markoch is a freelance financial copywriter who has been covering the market for over five years. He has been writing for InvestorPlace since 2019.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/02/7-strong-buy-stocks-under-20-dollars-that-are-begging-for-rate-cuts/">7 Strong Buy Stocks Under $20: February 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Strong Buy Stocks Under $20: February 2024

Ocugen, Community Health Systems among healthcare movers

Bionomics's BNC210 Shows Promise for PTSD Treatment: A Buy Rating Analysis

Maxim Group analyst Jason McCarthy has maintained their bullish stance on BNOX stock, giving a Buy rating on March 21. Jason McCarthy has given his...

Buy Rating Affirmed for Bionomics' BNC210 Following Promising PTSD Study Results

ACRS

AEHR

AGFY

AGRI

BEKE

BILI

BKSY

BLDE

CNXA

CORT

DADA

GRPN

LIFW

MOTS

MYNZ

NEXI

OCGN

RILY

ROMA

SPRC

TIVC

TNON

TPST

VERV

VTGN

XPEV

Small Cap

Opinion

Press Releases

Thinking about buying stock in Blue Apron Holdings, OceanPal, OPKO Health, Bionomics, or Aytu Biopharma?

Thinking about buying stock in Femasys Inc, Bionomics, micromobility.com, Uranium Energy Corp., or Burgerfi International?

Health Care

Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder

Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting

Bionomics to Present at Biotech Showcase™ 2024

Bionomics Provides a Review of 2023 and of 2024 Plans

Small-Cap Nasdaq Stocks to Watch Now! VTAK, BNOX, INBS, DYAI, KAVL

Bionomics to Present at the 2024 BIO CEO & Investor Conference

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder